Concepedia

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib

Massimo Breccia, Francesca Palandri, Anna Paola Iori, Elisabetta Colaci, Roberto Latagliata, Fausto Castagnetti, G Torelli, Sara Veronica Usai, Veronica Valle, Giovanni Martinelli,

Leukemia Research · 2009 · 41 citations · 11 references

DOI

Concepts

References

11

1994 Consensus Conference on Acute GVHD Grading.

Donna Przepiorka, Daniel Weisdorf, Peyton Martin et al. · PubMed · 1995 · 5.1K citations

, , +6

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann et al. · Blood · 2007 · 745 citations · Full text

, , +9

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

Richard T. Silver, Steven H. Woolf, Rüdiger Hehlmann et al. · PubMed · 1999 · 381 citations

, , +13

New Malignancies After Blood or Marrow Stem-Cell Transplantation in Children and Adults: Incidence and Risk Factors

K. Scott Baker, Todd E. DeFor, Linda J. Burns et al. · Journal of Clinical Oncology · 2003 · 319 citations

, , +17

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hm Kantaijian · Blood · 2007 · 143 citations

, , +9